In 2021, high expression of CEACAM6 was observed in precancerous lesions of GC, leading to the design of a new probe called CEACAM6 mAb-IRDye800CW, which can label gastric mucosal dysplasia obtained through endoscopic submucosal dissection (ESD) [33]. The gene discussed is CEACAM6; the disease is gastric cancer.